PZPanghu Zhou

Panghu Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Panghu Zhou has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Huangming Zhuang

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China; Central Laboratory of Renmin Hospital of Wuhan University, Wuhan, China

    13 shared publications
  • Xunshan Ren

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China; Central Laboratory of Renmin Hospital of Wuhan University, Wuhan, China

    12 shared publications
  • Yuelong Zhang

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China

    10 shared publications
  • Fuze Jiang

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China

    6 shared publications
  • Bo Qiu

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, China

    5 shared publications
  • Huajie Li

    Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, China

    5 shared publications

Latest Publications

  • Open Access

    Spermine Alleviates Chondrocyte Senescence and Extracellular Matrix Degradation by Suppressing NF-κB Signaling, with Odc1 Acting as a Potential Upstream Regulator

    by Rui Shi, Rongling Feng, Junming Zhu, Panghu Zhou

    Osteoarthritis (OA) is a prevalent degenerative joint disease with no disease-modifying therapy currently available. Spermine (SPM), a natural polyamine, shows therapeutic potential, but its role and mechanism in OA remain unclear. In this study, SPM expression was examined in OA cartilage, and the effects of exogenous SPM on chondrocyte senescence and extracellular matrix degradation were assessed in vitro and in a rat OA model. Bioinformatics analysis and Odc1 knockdown experiments were performed to identify the upstream regulator of SPM. The results showed that SPM was significantly downregulated in TBHP-stimulated chondrocytes. Exogenous SPM supplementation alleviated chondrocyte senescence, inhibited matrix degradation, and attenuated cartilage degeneration in vivo. Mechanistically, SPM inhibited NF-κB signaling, and Odc1 was identified as a key upstream regulator of SPM. In conclusion, SPM alleviates chondrocyte senescence and matrix degradation in vitro and attenuates OA progression in vivo. These effects are partially achieved by suppressing NF-κB signaling and upregulating Odc1, indicating that SPM is a promising therapeutic candidate for OA.

  • Open Access

    Bioorthogonal epigenetic anchoring of heterochromatin to the nuclear lamina reverses senescence and osteoarthritis

    by Xunshan Ren, Huangming Zhuang, Junming Zhu, Hongbao Jiang, Jinxuan Zhang, Yuelong Zhang, Rongling Feng, Rui Shi, Ruijun Zhang, Le Li, et al.


  • Open Access

    Fucoxanthin alleviates chondrocyte inflammation and osteoarthritis by modulating the JAK2/STAT3 signaling pathway

    by Miradj Siddick Adam, Huangming Zhuang, Xunshan Ren, Yuelong Zhang, Panghu Zhou

    Osteoarthritis (OA) is the most common type of joint degeneration and is a leading cause of chronic disability worldwide. OA is characterized by progressive cartilage degradation, synovial inflammation and oxidative stress within the joint microenvironment. Current pharmacological treatments primarily provide symptomatic relief and are often associated with substantial adverse effects, highlighting the need for new and safe disease‑modifying agents. Fucoxanthin (FUC), a carotenoid pigment found in brown algae, exhibits antioxidant, anti‑inflammatory and chondroprotective properties. Although FUC may have therapeutic effects in OA, the exact mechanisms remain unclear. In the present study, in a post‑traumatic OA rat model induced by anterior cruciate ligament transection, intra‑articular administration of FUC (200 mg/kg) substantially protected the articular cartilage architecture and inhibited proteoglycan loss. In IL‑1β‑stimulated primary rat chondrocytes, FUC markedly decreased the levels of proinflammatory cytokines (IL‑6 at both the mRNA and protein levels and IL‑1β at the protein level) as well as cartilage‑degrading enzymes (MMP3, MMP13 and a disintegrin and metalloproteinase with thrombospondin motifs 5) at the mRNA and protein levels. Furthermore, the chondroprotective and anti‑inflammatory effects of FUC were largely abrogated by RO8191, a selective Janus kinase (JAK)2/STAT3 pathway activator, suggesting that inhibition of the JAK2/STAT3 signaling pathway contributes to FUC‑mediated protective effects. The antioxidant capacity of FUC was evaluated using DPPH and hydroxyl radical scavenging assays, while intracellular reactive oxygen species (ROS) levels in IL‑1β‑stimulated chondrocytes were measured by fluorescence microscopy. FUC demonstrated a dose‑dependent free radical scavenging activity and significantly reduced IL‑1β‑induced intracellular ROS generation in chondrocytes (P<0.05). These findings suggest that FUC may represent a candidate multitarget natural compound for OA that can target oxidative stress, inflammation and extracellular matrix degradation via the JAK2/STAT3 signaling axis. Future investigations should determine the optimal pharmaceutical delivery system, the pharmacokinetics and tissue distribution associated with both local and systemic delivery of FUC, as well as the long‑term safety and efficacy in larger preclinical models and human trials.

  • Open Access

    Human umbilical cord mesenchymal stem cells decellular matrix alleviates chondrocyte senescence by inhibiting the STING-NF-κB pathway

    by Yuelong Zhang, Xunshan Ren, Huangming Zhuang, Huajie Li, Miradj Siddick Adam, Rongling Feng, Junming Zhu, Panghu Zhou

    Osteoarthritis (OA), characterized by synovial inflammation, articular cartilage degeneration, and structural changes of subchondral bone and periarticular tissues, represents a major unmet clinical challenge. Targeting senescent chondrocytes has emerged as a promising therapeutic strategy of OA. Human umbilgratical cord mesenchymal stem cells (hUCMSCs) have shown potential in OA treatment through paracrine mechanisms, but their clinical translation is limited by challenges in cell viability control and safety concerns. hUCMSCs decellular extracellular matrix (hUCMSCs-dECM) can target senescent chondrocytes to alleviate senescence in OA. Stimulator of interferon gene (STING) can promote chondrocyte senescence in OA through the activation of NF-κB signaling, and inhibition of STING may provide a novel approach for OA treatment. Here, we demonstrated that hUCMSCs-dECM attenuated chondrocyte senescence in vivo and in vitro by inhibiting the STING-NF-κB pathway, which would provide a novel approach for OA treatment.


  • Open Access

    Implications of mechanosensitive ion channels in the pathogenesis of osteoarthritis: a comprehensive review

    by Yuelong Zhang, Huangming Zhuang, Xunshan Ren, Panghu Zhou

    Osteoarthritis (OA) is the predominant cause of joint pain and limited mobility in older people, and its prevalence is increasing as the population ages. Given the lack of effective therapeutic interventions, the disability rate associated with OA is a staggering 53%, which significantly affects the wellbeing of those affected and represents a significant social and family financial burden. Consequently, OA has emerged as a pressing social and public health concern globally. Various forms of mechanical strain, such as dynamic compression, fluid shear, tissue shear, and hydrostatic pressure, serve as crucial physical stimuli perceived by chondrocytes. Recent studies indicate that aberrant mechanical loading represents a fundamental risk factor for OA. Upon exposure to mechanical loading, chondrocytes translate mechanical cues into chemical signals primarily via mechanosensitive ion channels, resulting in alterations in cartilage metabolism. Numerous studies have demonstrated the significance of mechanosensitive ion channels in the pathogenesis of OA, suggesting that therapeutic interventions targeting these channels on chondrocytes may offer potential benefits.


  • Open Access

    Management of posterior cruciate ligament injuries: an expert consensus from 17 countries

    by Shuguang Gao, Jiahao Meng, Chao Zeng, Joan C. Monllau, Robert F. LaPrade, Timothy N. Taft, Jeffrey H. Berg, Michael J. Medvecky, Kevin R. Stone, Michael J. Scarcella, et al.

    Background: Posterior cruciate ligament (PCL) injury is a relatively common musculoskeletal condition. However, there is currently a lack of consensus on decision-making, treatment and postoperative management for such injuries. Objectives: To use the modified Delphi method to reach expert consensus on the management of PCL injury. Methods: A literature search of PubMed, Cochrane Library, Embase, and Web of Science for articles up to 17 October 2024, to support the development of recommendation statements. An Expert Panel of 90 experienced clinicians from orthopedics and sports medicine participated in a two-round Delphi process. Each statement was evaluated in two parts: the first part assessed content appropriateness (score of 7–9 indicating appropriateness and 4–6 indicating possible appropriateness), while the second part assessed agreement (score of 5–9 indicating agreement). Results: The panel members developed 11 statements using the Delphi process, addressing the following topics: (1) clinical decision-making, (2) treatment, and (3) postoperative management about PCL injuries. The final consensus was reached on 11 statements and we eventually translated these statements into a corresponding table of expert recommendations. Conclusion: Consensus was reached on 11 statements regarding three aspects of PCL injury management. These findings provide a foundation for developing evidence-based guidelines that can enhance clinical decision-making, improve treatment strategies, and optimize postoperative care for patients with PCL injuries.


  • Open Access

    Cartilage-targeting peptide-modified cerium oxide nanoparticles alleviate oxidative stress and cartilage damage in osteoarthritis

    by Huangming Zhuang, Xunshan Ren, Huajie Li, Yuelong Zhang, Panghu Zhou

    Osteoarthritis (OA) is a degenerative joint disease that leads to a substantial decline in the well-being of older individuals. Chondrocyte senescence and the resultant damage to cartilage tissue, induced by elevated levels of reactive oxygen species within the joint cavity, are significant causative factors in OA development. Cerium oxide nanoparticles (CeONPs) present a promising avenue for therapeutic investigation due to their exceptional antioxidant properties. However, the limited effectiveness of drugs in the joint cavity is often attributed to their rapid clearance by synovial fluid. Polyethylene glycol-packed CeONPs (PEG-CeONPs) were synthesized and subsequently modified with the cartilage-targeting peptide WYRGRLGK (WY-PEG-CeO). The antioxidant free radical activity and the mimetic enzyme activity of PEG-CeONPs and WY-PEG-CeO were detected. The impact of WY-PEG-CeO on chondrocytes oxidative stress, cellular senescence, and extracellular matrix degradation was assessed using in vitro assays. The cartilage targeting and protective effects were explored in animal models. WY-PEG-CeO demonstrated significant efficacy in inhibiting oxidative stress, cellular senescence, and extracellular matrix degradation in OA chondrocytes. The underlying mechanism involves the inhibition of the PI3K/AKT and MAPK signaling pathways. Animal models further revealed that WY-PEG-CeO exhibited a prolonged residence time and enhanced penetration efficiency in cartilage tissue, leading to the attenuation of pathological changes in OA. These findings suggest that WY-PEG-CeO exerts therapeutic effects in OA by inhibiting oxidative stress and suppressing the over-activation of PI3K/AKT and MAPK signaling pathways. This investigation served as a fundamental step towards the advancement of CeONPs-based interventions, providing potential strategies for the treatment of OA.


  • Top Cited Papers
    Open Access

    β‐Hydroxybutyrate enhances chondrocyte mitophagy and reduces cartilage degeneration in osteoarthritis via the HCAR2/AMPK/PINK1/Parkin pathway

    by Huangming Zhuang, Xunshan Ren, Yuelong Zhang, Huajie Li, Panghu Zhou

    Osteoarthritis (OA) is widely recognized as the prevailing joint disease associated with aging. The ketogenic diet (KD) has been postulated to impede the advancement of various inflammatory ailments. β‐Hydroxybutyrate (βOHB), a prominent constituent of ketone bodies, has recently been proposed to possess crucial signaling capabilities. In this study, we propose to explore the role and mechanism of βOHB in OA. Tissue staining and inflammatory factor assay were employed to evaluate the impacts of KD and βOHB on OA rats. The oxidative stress conditions in chondrocytes were induced using tert‐butyl hydroperoxide (TBHP). The mechanisms were determined using the siRNA of hydroxycarboxylic acid receptor 2 (HCAR2), the antagonist of adenosine monophosphate‐activated protein kinase (AMPK), and the inhibitor of mitophagy. The administration of KD demonstrated a reduction in pathological damage to cartilage, as well as a decrease in plasma levels of inflammatory factors. Furthermore, it resulted in an increase in the concentration of βOHB in the blood and synovial fluid. In vitro experiments showed that βOHB facilitated mitophagy and adenosine triphosphate production. Besides, βOHB mitigated chondrocyte senescence, inflammatory factors secretion, extracellular matrix degradation, and apoptosis induced by TBHP. Subsequent investigations indicated that the protective effects of βOHB were no longer observed following the knockdown of HCAR2, the antagonist of AMPK, or the inhibitor of mitophagy. Moreover, in vivo studies suggested that βOHB played a protective role by targeting the HCAR2‐AMPK‐PINK1 axis. In conclusion, βOHB enhanced chondrocyte mitophagy through the HCAR2/AMPK/PINK1/Parkin pathway, offering a potential therapeutic approach for the treatment of OA.